Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bladder urothelium carcinoma detection combined marker

A technology of urothelial cancer and markers, which is applied in the determination/testing of microorganisms, biochemical equipment and methods, DNA/RNA fragments, etc., which can solve the problems of increased levels and low specificity, and reduce the workload of sequencing , Improving the detection efficiency and accuracy, and the effect of good diagnostic performance

Inactive Publication Date: 2021-06-01
苏州仁端生物医药科技有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Testing for these markers provides better sensitivity than cytology, but is less specific because elevated levels of these markers are also commonly observed in patients with non-malignant disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bladder urothelium carcinoma detection combined marker
  • Application of bladder urothelium carcinoma detection combined marker
  • Application of bladder urothelium carcinoma detection combined marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Embodiment 1: Sample collection and processing.

[0044] This study was approved by the Ethics Committee of Renji Hospital. The research process complied with the requirements of the American General Rules of Ethics. Written informed consent was obtained from all patients. A total of 119 newly diagnosed subjects with suspected UBC were prospectively recruited in Renji Hospital. 40 ml of first morning urine was collected at home before surgical intervention. At clinical visits, 10 ml blood samples and paired peripheral blood mononuclear cell (PBMC) controls were collected for sequencing. In addition, fresh-frozen tissue specimens are obtained during diagnostic biopsy or curative surgery. Patients with an early diagnosis other than UBC or who did not receive urine / tissue samples were excluded.

[0045] Use a urine collection cup to collect the patient's morning urine and transfer it to four vacuum tubes, and thoroughly mix the urine sample with the pre-perfused prese...

Embodiment 2

[0046] Example 2: DNA extraction, library construction, capture and sequencing.

[0047] Plasma cfDNA and urine cfDNA were extracted from blood and urine samples, respectively, using the QIAamp Circulating Nucleic Acid Kit (Qiagen). Quantity and quality of purified cfDNA were checked with Qubit Fluorometer (Thermo Fisher Scientific) and Bioanalyzer 2100 (Agilent). For samples with severe genomic contamination extracted from intact cells, select DNA fragments using the magnetic bead method to remove larger diameter DNA fragments. Genomic DNA (gDNA) in PBMCs and frozen tumor tissues was extracted using DNeasy Blood Tissue DNA Extraction Kit (Qiagen). 250 ng gDNA was digested and purified.

[0048] Libraries were constructed using 20 ng of cfDNA extract or 40 ng of gDNA fragments, including end repair, dA tailing, and adapter ligation. The ligated library fragments were amplified by PCR with appropriate adapters. The amplified DNA library was further checked using Bioanalyzer...

Embodiment 3

[0049] Example 3: Analysis of gDNA sequencing data.

[0050] The gDNA data is analyzed using the in-house analysis pipeline developed by Huidu Medical, starting from the raw sequencing data (BCL file) and outputting the final somatic mutation call of the tumor DNA (tDNA). Briefly, the pipeline begins with adapter trimming, barcode checking, and correction. The cleaned paired FASTQ files were aligned to the human reference genome version hg19 using the BWA alignment tool. Identify candidate variants, including point mutations, small insertions, and small deletions, in target regions covered by the PredicinePLUS Assay Panel. Filters variants with low quality, location score, and other quality metrics. Variants with an allele frequency 0.5%, ExAC, gnomAD, and KAVIAR), and allele frequencies >5% Variants detected in paired PBMC samples. Candidate somatic mutations were further filtered based on gene annotations, identifying somatic mutations occurring in protein coding regions...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of a bladder urothelium carcinoma detection combined marker, and belongs to the technical field of molecular medicine. The bladder urothelium carcinoma detection combined marker comprises the following gene combinations: TERT, TP53, FGFR3, PIK3CA and ARID1A. According to the invention, it is found for the first time that a combination of five genes of TERT, TP53, FGFR3, PIK3CA and ARID1A can accurately diagnose bladder urothelial carcinoma. Compared with an original method, the method has the advantages that the five core gene detection combinations reduce the sequencing workload by 40 times, and good diagnostic performance is maintained.

Description

technical field [0001] The invention belongs to the technical field of biological genes and immune detection, and in particular relates to the application of a combined marker for bladder urothelial cancer detection. Background technique [0002] Urothelial bladder carcinoma (UBC) is a common malignant tumor of the urinary tract, with an annual incidence of 549,393 worldwide. About 75% of primary UBC cases are non-muscle invasive bladder cancer (NMIBC). Transurethral resection is generally used for treatment, but the recurrence rate is high, and long-term and timely follow-up is the key. In contrast, muscle-invasive bladder cancer (MIBC) accounts for a smaller proportion but has a worse prognosis, and the current standard of care is neoadjuvant chemotherapy followed by radical cystectomy. Owing to the recent success of immunotherapies (eg, pembrolizumab) and targeted agents (eg, erdafitinib), individualized therapy is a viable strategy to improve patient outcomes. Therefor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/11
CPCC12Q1/6886C12Q2600/118C12Q2600/156
Inventor 陈海戈庄光磊张瑞赟臧婧羽
Owner 苏州仁端生物医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com